Abstract
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare real-world, 6-month glycated haemoglobin (HbA1c) and weight outcomes for exenatide once weekly with those for dulaglutide and albiglutide. The study included 2465 patients: exenatide once weekly, n = 2133; dulaglutide, n = 201; and albiglutide, n = 131. The overall mean (standard deviation [s.d.]) age was 60 (11) years and 54% were men; neither differed among the comparison groups. The mean (s.d.) baseline HbA1c was similar in the exenatide once-weekly (8.3 [1.7]%) and dulaglutide groups (8.5 [1.5]%; P =.165), but higher in the albiglutide group (8.7 [1.7]%; P <.001). The overall mean (s.d.) HbA1c change was −0.5 (1.5)% (P <.001) and this did not differ among the comparison groups in either adjusted or unadjusted analyses. The mean (s.d.) weight change was −1.4 (4.7) kg for exenatide once weekly and −1.6 (3.7) kg for albiglutide (P =.579), but was greater for dulaglutide, at −2.7 (5.7) kg (P =.001). Outcomes were similar in subsets of insulin-naive patients with baseline HbA1c ≥7.0% or ≥9.0%. All agents significantly reduced HbA1c at 6 months, with no significant differences among agents or according to baseline HbA1c in insulin-naive subgroups.
Original language | English (US) |
---|---|
Pages (from-to) | 468-473 |
Number of pages | 6 |
Journal | Diabetes, Obesity and Metabolism |
Volume | 20 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2018 |
Externally published | Yes |
Keywords
- GLP-1
- database research
- dulaglutide
- exenatide
- glycaemic control
- type 2 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology